Medical News

RSS

No survival benefit with dacomitinib in pretreated patients with advanced NSCLC

The irreversible, pan-epidermal growth factor receptor tyrosine kinase inhibitor dacomitinib does not offer a survival benefit in pretreated patients with advanced or metastatic non-small-cell lung cancer, phase III trial results show.

14 Nov 2014

Postoperative radiation benefits N2 resected NSCLC patients

Patients with resected, margin-negative non-small-cell lung cancer with mediastinal node metastases derive significant benefit from postoperative radiotherapy, US researchers report.

14 Nov 2014

Chaetocin synergistic with TKIs against CML cells

Chaetocin, a mycotoxin that increases oxidative stress, can complement the activity of tyrosine kinase inhibitors in chronic myeloid leukaemia by overcoming innate resistance mediated by secreted bone marrow stromal cytokines and growth factors, researchers report.

14 Nov 2014

Massachusetts Eye and Ear offers femtosecond laser technology to Boston-area patients

Patients choosing cataract surgery at Massachusetts Eye and Ear may now elect to have laser-assisted cataract surgery with the femtosecond LensSx® Laser. The hospital is one of the few in New England to offer the advanced technology, which enables surgeons to more precisely perform cataract surgery aided by a computer-controlled laser.

14 Nov 2014

New technology improves lung cancer detection during radiation therapy

Researchers from Loyola University Chicago Stritch School of Medicine have developed a technology that improves the detection of tumors during radiation therapy for early-stage lung cancer.

14 Nov 2014

UNC researchers develop new approach to block KRAS oncogene

Researchers from the UNC School of Medicine and colleagues at The University of Texas MD Anderson Cancer Center have developed a new approach to block the KRAS oncogene, one of the most frequently mutated genes in human cancer.

14 Nov 2014

Biosafe gears up its activities in China with major expansion of Shanghai-based operations

Following the full registration of its product range by the Chinese FDA last April, Biosafe is gearing up its activities in the People's Republic of China with a major expansion of its Shanghai-based operations, including staffing and facilities consolidation.

14 Nov 2014

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China, today reported financial results for the three and nine months ended September 30, 2014.

14 Nov 2014

PDL BioPharma receives $30.3M to conclude revenue interest contract with AxoGen

PDL BioPharma, Inc. (PDL) today announced that the company has received $30.3 million, in addition to previously received revenue interest payments, to conclude PDL's revenue interest agreement with AxoGen, Inc.

14 Nov 2014

Valeant Pharmaceuticals hosts ribbon-cutting ceremony to celebrate renovation of U.S. headquarters in NJ

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today celebrated the completion of renovations to its U.S. headquarters in Bridgewater, New Jersey with a ribbon-cutting ceremony.

14 Nov 2014

A single gene mutation can halve the risk of heart disease

Recent research has shown that inactivation of a single gene reduces the risk of heart attack by 50%.

14 Nov 2014

Bacterial protein flagellin can prevent and cure rotavirus infection

Activation of the innate immune system with the bacterial protein flagellin could prevent and cure rotavirus infection, which is among the most common causes of severe diarrhea, says a Georgia State University research team that described the method as a novel means to prevent and treat viral infection.

14 Nov 2014

China Pharma’s revenues decrease $5.5M to 31% in third quarter 2014

China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma" or the "Company"), an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced its financial results for the three months ended September 30, 2014.

14 Nov 2014